Cardiovascular events as the effect of targeted therapy;Powikłania kardiologiczne jako powikłania terapii celowanych

Wspolczesna Onkologia

Volumn 12, Issue 7, 2008, Pages 318-323

  Szmit, Sebastian ^a,b   Opolski, Grzegorz ^b   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b WARSZAWSKI UNIWERSYTET MEDYCZNY   (Poland)

Author keywords

Anti HER2 therapy; Cardiovascular events; Heart failure; Hypertension; Small molecule tyrosine kinase inhibitors; Targeted therapies; Thromboembolic complications

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CYTOSTATIC AGENT; IMATINIB; LAPATINIB; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ACUTE CORONARY SYNDROME; CANCER RESEARCH; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CELL METABOLISM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HEART DISEASE; HEART MUSCLE CELL; HEART MUSCLE NECROSIS; HEART PROTECTION; HUMAN; HYPERTENSION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SOLID TUMOR; THROMBOEMBOLISM;

EID: 66449096999     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-344 (Pubitemid 46652481)
2. Wiczyńska B, Rolski J. Terapia celowana Czȩść I. Mechanizmy przesyłania sygnałów przy udziale receptorów o aktywności kinazy tyrozynowej. Współcz Onkol 2007; 11: 331-6.
3. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187 (Pubitemid 41058349)
4. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916 (Pubitemid 44175142)
5. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124 (Pubitemid 46089672)
6. Dyck JR, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 2006; 574: 95-112.
7. Branca MA. Multi-kinase inhibitors create buzz at ASCO. Nat Biotechnol 2005; 23: 639.
8. Pfizer. Sutent (sunitinib) Prescribing Information. Available at: 〈http://www.pfizer.com/pfizer/download/uspi-sutent. pdf〉(2007).
9. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-38.
10. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145: 660-664 (Pubitemid 46768841)
11. Hsieh PC, MacGillivray C, Gannon J, Cruz FU, Lee RT. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006; 114: 637-644 (Pubitemid 44252305)
12. Terai K, Hiramoto Y, Masaki M, Sugiyama S, Kuroda T, Hori M, Kawase I, Hirota H. AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress. Mol Cell Biol 2005; 25: 9554-9575 (Pubitemid 41507855)
13. Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23: 329-36.
14. Bayer Pharmaceuticals. Nexavar (sorafenib) Prescribing Information. Available at: 〈http://www. univgraph. com/ bayer/inserts/nexavar. pdf〉(2006).
15. Chen J, Fujii K, Zhang L, Roberts T, Fu H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulated kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci U S A 2001; 98: 7783-7788 (Pubitemid 32642638)
16. Muslin AJ. Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc Med 2005; 15: 225-9.
17. Yamaguchi O, Higuchi Y, Hirotani S, et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc Natl Acad Sci U S A 2003; 100: 15883-8.
18. Yamaguchi O, Watanabe T, Nishida K, et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004; 114: 937-43.
19. Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. Raf- -1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 2004; 110: 718-723 (Pubitemid 39056272)
20. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005; 115: 2108-2118 (Pubitemid 41134152)
21. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006; 47: 887-893 (Pubitemid 44297560)
22. Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007; 446: 444-8.
23. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445: 661-665 (Pubitemid 46232887)
24. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9: 117-23.
25. Figlin R, McDermott D, Gabrail N, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. Proc Am Soc Clin Oncol 2007; 25: (abstract 5011).
26. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512 (Pubitemid 46630627)
27. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31.
28. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193 (Pubitemid 46178407)
29. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A. A phase I/II doseescalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30 (5 Suppl. 16): 117-124 (Pubitemid 37433402)
30. Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992; 10: 1386-9.
31. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
32. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
33. Crone SA., Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459-465 (Pubitemid 34546747)
34. Chien KR. Stress pathways and heart failure. Cell 1999; 98: 555-8.
35. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA, Kelly RA.. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 1998; 273: 10261-10269 (Pubitemid 28227629)
36. Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates ERBB2-dependent Src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006; 41: 228-235 (Pubitemid 44080212)
37. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378: 394-8.
38. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 1995; 378: 390-4.
39. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature 1995; 378: 386-90.
40. Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the Erb- B2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A 2002; 99: 8880-8885 (Pubitemid 34693652)
41. Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 2006; 24: 3735-3746 (Pubitemid 46622312)
42. Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ, Rosenzweig A. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004; 44: 2231-2238 (Pubitemid 39576044)
43. Lemmens K, Doggen K, De Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: implications for therapy of heart failure. Circulation 2007; 116: 954-960 (Pubitemid 47300920)
44. Doggen K, Lemmens K, De Keulenaer GW. Effects of vivo neuregulin-1/ErbB activation on diabetes-induced myocardial dysfunction in the rat. European Congress of Heart Failure, Milan 2008.
45. Doggen K, Ray L, Mathieu M, Mc Entee K, Lemmens K, De Keulenaer GW. Direct evidence for activation of the neuregulin-1/ErbB system in myocardium of dogs with pacing-induced heart failure. European Congress of Heart Failure, Milan 2008.
46. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792 (Pubitemid 32222155)
47. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221 (Pubitemid 34177427)
48. Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 2006; 11: 857-867 (Pubitemid 44373758)
49. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in nodepositive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-9.
50. Bengala C, Zamagni C, Pedrazzoli P, et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 2006; 94: 1016-20.
51. Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65.
52. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V, Lenihan DJ. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-7826 (Pubitemid 46657379)
53. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322-9.
54. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 2006; 33: S2-S7.
55. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007; 369: 29-36.
56. Burris HA 3rd, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-13.
57. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743 (Pubitemid 46021510)
58. Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83: 679-686 (Pubitemid 351810568)